FindTrial
Sign In

Combination of CHA2DS2-VASc score and hematological parameters in predicting no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segement elevation myocardial infarction

Combination of CHA2DS2-VASc score and hematological parameters in predicting no-reflow phenomenon after primary percutaneous coronary intervention in patients with ST-segement elevation myocardial infarction

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021318
Enrollment
Unknown
Registered
2019-02-13
Start date
2019-02-13
Completion date
Unknown
Last updated
2019-02-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

STMEMI

Interventions

No-reflow group and normal blood flow group:nil

Sponsors

Shengjing Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with ST-segment elevation myocardial infarction diagnosed and stented.

Exclusion criteria

Exclusion criteria: 1. Recent surgical history; 2. Chronic cardiac insufficiency, cardiomyopathy and severe valvular disease; 3. Severe liver and kidney dysfunction patients; 4. Recent infectious diseases; 5. Pregnancy, tumor, hyperthyroidism, infection, autoimmune diseases, blood system Disease patients; 6. Data is incomplete.

Design outcomes

Primary

MeasureTime frame
CHA2DS2-VASc score;—

Countries

China

Contacts

Public ContactShumei Ma
15909837986@163.com+86 15909837986

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026